Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia.
Studies suggest that the omega-3 fatty acid supplementation may be beneficial in reducing symptom severity in schizophrenia. The mechanism(s) underlying the clinical effect is not known. Serotonin (5-HT) has been implicated in the pathophysiology of schizophrenia and in the mechanism of some antipsychotic agents. 5-HT receptors are known to be modified by omega-3 fatty acids. We examined whether supplementation with the omega-3 fatty acid eicosapentaenoic acid (EPA)-modified 5-HT amplified ADP-induced platelet aggregation in patients with schizophrenia. Two grams of ethyl-EPA was administered daily for 6 months supplementally to ongoing antipsychotic treatment in 12 patients with chronic schizophrenia, using an open-label design. Red blood cell membrane fatty acids and platelet functions (platelet aggregation and dense granule secretion) were monitored at baseline, 1-, 3- and 6-months. The EPA levels were elevated more than five-fold in RBC membranes of all patients after 3 months supplementation, indicating a high degree of compliance. Consistent with previous reports, there was inhibition of ADP-induced platelet aggregation by EPA supplementation. Moreover, EPA markedly enhanced the 5-HT responsivity as measured by the magnitude of 5-HT amplification on ADP-induced platelet aggregation. Previously, we have demonstrated a significant inverse correlation between 5-HT responsivity and psychosis severity in unmedicated patients with schizophrenia. Taken together, the present data support the notion that EPA may be mediating its therapeutic effects in schizophrenia via modulation of the 5-HT2 receptor complex.
Yao
Jeffrey K
JK
VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. jkyao@pitt.edu
Magan
Sharon
S
Sonel
Ali F
AF
Gurklis
John A
JA
Sanders
Richard
R
Reddy
Ravinder D
RD
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004910:Erythrocyte Membrane / Q000378:metabolism; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D044348:Receptors, Serotonin, 5-HT2 / Q000378:metabolism*; D012559:Schizophrenia / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D012701:Serotonin / Q000378:metabolism*
D044348:Receptors, Serotonin, 5-HT2; D012701:Serotonin; D000244:Adenosine Diphosphate; D015118:Eicosapentaenoic Acid